Efficacy and tolerability of a spray formulation containing Visnadine in women self-reporting sexual symptoms: a randomized double-blind placebo-controlled pilot study

Bernorio, R; Piloni, S.; Mori, Graziela Garrido; Prunas, A; Bosoni, David; Nappi, Rossella E.

doi:10.1007/s40618-017-0801-0

Cited by 8 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 3 Visadine interventions are applied in different ways: One of them evaluated the use of spray on demand [15], another evaluated both on demand and daily use, without placebo group [20], whilst a further study assessed the use of Visnadine oil [21]. Both spray and oil produced differences in the FSFI score with respect to placebo [15] [21], although the oil intervention was a pilot study. The other study found results to indicate the efficacy of both daily and on-demand use in women with HSDD [20].…”

Section: Resultsmentioning

confidence: 99%

The Use of Natural Products for the Treatment of Female Sexual Dysfunction: A Systematic Review of Randomized Clinical Trials

Jurado¹,

Jouda-Benazouz²,

Mendoza-Huertas³

et al. 2020

ASM

View full text Add to dashboard Cite

Female sexual dysfunction (FSD) affects 40% of the world's females, most of which are disorders linked to desire or interest/excitement. Whilst all types of therapy that attempt to improve female sexual desire have long been established, the results are contradictory. Objective: To analyze all available evidence to validate the effectiveness of natural therapies in the treatment of FSD. Method: The study was registered at http://www.prospero.org (CRD42019127700). We searched the Institute for Scientific Information Web of Knowledge, MEDLINE, Pubmed, Scopus and Cochrane databases for all articles published in peerreviewed journals in April 2019 (in any language). The PICOS standard is women with FSD; (intervention) of any type of Natural therapy; (outcome) primary outcome: frequency of changes, severity, and average mean scores on sexual symptoms measured with a validated instrument, secondary outcome: quality of life; (study design) and randomized clinical trial (RCT). Results: The literature search strategy identified 95 articles, 81 of which were excluded at the different search stages. Finally, we systematically reviewed 15 RCTs, 11 of which referred to primary FSD, and four of which analyzed women with drug-induced FSD (DFSD). Most of them analyzed hypoactive sexual desire disorder. Although differences related to placebo were found in most people, the majority of the studies are considered to be of poor quality and low external effectiveness. Conclusion: Although the quality of the evidence is not high, most natural product interventions appear to improve FSD, particularly hypoactive sexual desire disorders including those categorized as primary and drug-induced.

show abstract

Section: Resultsmentioning

confidence: 99%

The Use of Natural Products for the Treatment of Female Sexual Dysfunction: A Systematic Review of Randomized Clinical Trials

Jurado¹,

Jouda-Benazouz²,

Mendoza-Huertas³

et al. 2020

ASM

View full text Add to dashboard Cite

show abstract

“…It interacts with the type 1 calcium channels at the level of the smooth muscles, causing an increase in the local flow. It has been observed that the local administration of a spray based on visnadine 10 minutes before sexual intercourse has a positive effect, so it is also a candidate among the non-hormonal alternatives to be used in the treatment of GSM in BCS [25].…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Choices for Genitourinary Syndrome of Menopause (GSM) in Breast Cancer Survivors: A Systematic Review and Update

Merlino¹,

D’Ovidio²,

Piccioni³

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

(1) Background: Genitourinary syndrome of menopause (GSM) is a medical condition that can affect breast cancer survivors (BCS). This is a complication that often can occur as a result of breast cancer treatment, causing symptoms such as vaginal dryness, itching, burning, dyspareunia, dysuria, pain, discomfort, and impairment of sexual function. BCS who experience these symptoms negatively impact multiple aspects of their quality of life to the point that some of them fail to complete adjuvant hormonal treatment; (2) Methods: In this systematic review of the literature, we have analyzed possible pharmacological and non-pharmacological treatments for GSM in BCS. We reviewed systemic hormone therapy, local hormone treatment with estrogens and androgens, the use of vaginal moisturizers and lubricants, ospemifene, and physical therapies such as radiofrequency, electroporation, and vaginal laser; (3) Results: The data available to date demonstrate that the aforementioned treatments are effective for the therapy of GSM and, in particular, vulvovaginal atrophy in BCS. Where possible, combination therapy often appears more useful than using a single line of treatment; (4) Conclusions: We analyzed the efficacy and safety data of each of these options for the treatment of GSM in BCS, emphasizing how often larger clinical trials with longer follow-ups are needed.

show abstract

“…Chez la femme, l'utilisation de lubrifiant et/ou d'un traitement substitutif hormonal permet de diminuer la sécheresse vaginale et les dyspareunies. 22 Enfin, la présence d'une stomie mais aussi le cancer lui-même pouvant modifier l'image de soi, et de ce fait, entraîner des difficultés dans la relation de couple, le sujet est abordé lors de la consultation par le chirurgien. Si besoin, un sexologue est impliqué dans la prise en charge du patient.…”

Section: Des Dysfonctions Sexuelles Accessibles Au Traitementunclassified

Préservation de la fonction sexuelle : un défi pour le chirurgien colorectal

Liot¹,

Buchs²,

Klein³

et al. 2018

Revue Médicale Suisse

View full text Add to dashboard Cite

Les patients atteints d'un cancer du rectum présentent un risque accru de développer ou d'aggraver des troubles de la sexualité. Ces dysfonctions sont causées par la maladie (impact psychologique négatif, compression nerveuse dans le petit bassin) d'une part, et par les traitements (radio, chimiothérapie et chirurgie) d'autre part. Parmi ceux-ci, la chirurgie est responsable de la plupart des troubles sexuels, par lésion des plexus neurovégétatifs. Une évaluation de la sexualité des patients avant et après traitement, une connaissance précise de l'anatomie du petit bassin par le chirurgien ainsi qu'une prise en charge adaptée par des spécialistes (gynécologues, urologues, sexologues) constituent les étapes essentielles afin de diminuer le risque de survenue de troubles sexuels et leur impact sur la qualité de vie globale des patients. Preservation of sexual function : a challenge for the colorectal surgeonPatients with rectal cancer have an increased risk of developing sexual disorders. These dysfunctions are caused by the disease itself (negative psychological impact, nerve compression in the pelvis), as well as by the treatments (radiotherapy, chemotherapy and surgery). Most sexual disorders are due to the surgery and can be attributed to injuries of the retroperitoneal nerves. Sexuality assessment of patients before and after treatment, a precise knowledge of the pelvic anatomy by the surgeon, and an appropriate care by specialists (gynaecologists, urologists and sexologists) are essential to reduce the risk of sexual disorders and to minimize their impact on overall quality of life. LA SEXUALITÉ EN DANGER À CHAQUE ÉTAPE DU TRAITEMENTLe traitement du cancer du rectum implique différentes modalités telles que la chirurgie, la chimiothérapie et la radiothérapie. Chacune d'entre elles peut affecter la vie sexuelle des patients traités. Dans l'étude de Downing publiée en 2015, 30,1 % des patients ayant subi une radiothérapie préopératoire rapportaient des difficultés sexuelles vs 12,4 % des patients traités par proctectomie seule. 10 L'origine de ces difficultés est

show abstract

Efficacy and tolerability of a spray formulation containing Visnadine in women self-reporting sexual symptoms: a randomized double-blind placebo-controlled pilot study

Cited by 8 publications

References 29 publications

The Use of Natural Products for the Treatment of Female Sexual Dysfunction: A Systematic Review of Randomized Clinical Trials

The Use of Natural Products for the Treatment of Female Sexual Dysfunction: A Systematic Review of Randomized Clinical Trials

Therapeutic Choices for Genitourinary Syndrome of Menopause (GSM) in Breast Cancer Survivors: A Systematic Review and Update

Préservation de la fonction sexuelle : un défi pour le chirurgien colorectal

Contact Info

Product

Resources

About